Bronchoscopy vs. Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP)
Primary Purpose
Ventilator Associated Pneumonia
Status
Withdrawn
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Bronchoscopy
Clinical pulmonary infection score (CPIS)
Sponsored by
About this trial
This is an interventional treatment trial for Ventilator Associated Pneumonia focused on measuring Ventilator associated pneumonia, Intensive Care, Antibiotics, Mortality, Length of stay
Eligibility Criteria
Inclusion Criteria:
- Age >= 18 years
- Endotracheal intubation
- Suspected VAP with:
- New or progressive pulmonary infiltrates plus two of the following (In patients with pre-existing ALI or ARDS, physicians' suspicion of VAP with two of the listed criteria will be used.): Temperature > 38 C or < 36 C, WBC > 12,000/mL or < 4,000/mL, purulent endotracheal secretions.
- Patient or legally authorized representative is able to sign Informed Consent
Exclusion Criteria:
- Prison inmates
- Immunocompromised patients
- Participation in another trial conflicting with the design of the current trial
- Previous history of VAP during the same hospitalization
- Previous participation in the current study
- Concomitant non-pulmonary infection diagnosed within 3 days preceding the suspected VAP
- Patient's primary care provider does not want subject to be enrolled in the study
- Contraindications for bronchoscopy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
1
2
Arm Description
Bronchoscopy
CPIS
Outcomes
Primary Outcome Measures
14-day antibiotic free days
Secondary Outcome Measures
Mortality
Daily organ failure score
Length of hospital stay
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00588588
Brief Title
Bronchoscopy vs. Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP)
Official Title
Bronchoscopy Versus Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP): Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Due to inability to get support for the study
Study Start Date
January 2007 (undefined)
Primary Completion Date
May 2009 (Actual)
Study Completion Date
May 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Mayo Clinic
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The reported incidence of ventilator associated pneumonia (VAP) is 10 to 15 per 1,000 ventilator days. VAP leads to an excess cost exceeding $40,000 per patient and is associated with a crude mortality rate as high as 76%. The clinical criteria for the diagnosis of VAP have low specificity and may lead to unnecessary antibiotic use. The Clinical Pulmonary Infection Score (CPIS) and bronchoscopic approaches lower unnecessary antimicrobial use, antimicrobial resistance, and superinfection compared to the traditional clinical criteria.
Based on the available evidence and local microbiology data, we have developed a VAP management protocol guided by CPIS or bronchoalveolar lavage (BAL) in adults with suspected VAP. These two approaches have not been compared against each other. Although the diagnostic studies in the CPIS guided approach are inexpensive and easily available, BAL has the potential to minimize the unnecessary use of antibiotics and reduce the development of drug resistant pathogens.
In this study, we propose to test the hypothesis that BAL leads to a reduction in antibiotic use compared to CPIS in patients with suspected VAP. The study design will be a randomized, clinical trial comparing CPIS versus BAL. The primary outcome measure will be antibiotic utilization. The secondary outcome measures will be mortality, morbidity, development of resistant pathogens and superinfection and infection related financial burden.
Completion of this trial will help us identify the best approach to avoid unnecessary antibiotic utilization and minimize the development of resistant pathogens (with their associated morbidity and mortality) in critically ill patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventilator Associated Pneumonia
Keywords
Ventilator associated pneumonia, Intensive Care, Antibiotics, Mortality, Length of stay
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Bronchoscopy
Arm Title
2
Arm Type
Active Comparator
Arm Description
CPIS
Intervention Type
Procedure
Intervention Name(s)
Bronchoscopy
Intervention Description
Bronchoscopy procedure
Intervention Type
Procedure
Intervention Name(s)
Clinical pulmonary infection score (CPIS)
Intervention Description
Calculate CPIS
Primary Outcome Measure Information:
Title
14-day antibiotic free days
Time Frame
Day 14 of enrolment
Secondary Outcome Measure Information:
Title
Mortality
Time Frame
28 days
Title
Daily organ failure score
Time Frame
14 days
Title
Length of hospital stay
Time Frame
Hospital stay
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age >= 18 years
Endotracheal intubation
Suspected VAP with:
New or progressive pulmonary infiltrates plus two of the following (In patients with pre-existing ALI or ARDS, physicians' suspicion of VAP with two of the listed criteria will be used.): Temperature > 38 C or < 36 C, WBC > 12,000/mL or < 4,000/mL, purulent endotracheal secretions.
Patient or legally authorized representative is able to sign Informed Consent
Exclusion Criteria:
Prison inmates
Immunocompromised patients
Participation in another trial conflicting with the design of the current trial
Previous history of VAP during the same hospitalization
Previous participation in the current study
Concomitant non-pulmonary infection diagnosed within 3 days preceding the suspected VAP
Patient's primary care provider does not want subject to be enrolled in the study
Contraindications for bronchoscopy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bekele Afessa, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
16528014
Citation
Afessa B, Hubmayr RD, Vetter EA, Keegan MT, Swanson KL, Baddour LM, Cockerill FR 3rd, Peters SG. Bronchoscopy in ventilator-associated pneumonia: agreement of calibrated loop and serial dilution. Am J Respir Crit Care Med. 2006 Jun 1;173(11):1229-32. doi: 10.1164/rccm.200512-1899OC. Epub 2006 Mar 9.
Results Reference
background
Links:
URL
http://clinicaltrials.mayo.edu
Description
Mayo Clinic Clinical Trials
Learn more about this trial
Bronchoscopy vs. Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP)
We'll reach out to this number within 24 hrs